Adamas Pharmaceuticals announced that pooled Phase 3 data of Govocri extended release capsules for the treatment of dyskinesia
in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, were published online in CNS Drugs.
I'm very proud of the accomplishments made by the Adamas team in 2017, especially the approval and commercial availability of GOCOVRI, the first and only FDA-approved treatment for dyskinesia
in patients with Parkinson's disease receiving levodopa-based therapy," said Gregory T.
Prolonged prolonged exposure to the dopamine replacement drugs can lead to dyskinesia
, causing involuntary jerking and spasms of the whole body.
According to the company, INGREZZA (valbenazine) is a novel selective vesicular monoamine transporter 2 (VMAT2) inhibitor and is the first US FDA approved product indicated for the treatment of adults with tardive dyskinesia
Conclusions: Targeting nondopaminergic transmission could improve some motor symptoms in PD, especially the discomfort of dyskinesia
Background: Tardive dyskinesia
(TD) is characterized by abnormal and involuntary movements.
The Food and Drug Administration has approved valbenazine capsules for the treatment of tardive dyskinesia
(TD) is an iatrogenic movement disorder of various phenomenologies which has delayed onset, caused by Dopamine Receptor-Blocking Agents (DRBA), also called neuroleptics.
(TD) is a neuromuscular disorder that is characterized with involuntary, repetitive, and unintentional movements occurring during treatment or a short time after discontinuing treatment, which develops in response to long-term antipsychotic use.
Global Markets Direct's, 'Dyskinesia
- Pipeline Review, H1 2016', provides an overview of the Dyskinesia
However, with the progression of the disease, the vast majority of patients develop abnormal involuntary movements, known as L-DOPA-induced dyskinesia
(LID), limiting the ability of this drug to provide a satisfactory control of the motor manifestations.
It also reviews key players involved in the therapeutic development for Dyskinesia
and special features on late-stage and discontinued projects.